Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".
作者信息
Kim Donghee, Danpanichkul Pojsakorn, Wijarnpreecha Karn, Cholankeril George, Loomba Rohit, Ahmed Aijaz
机构信息
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):e180-e182. doi: 10.3350/cmh.2025.0125. Epub 2025 Feb 13.
Abstract
摘要
相似文献
1
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".
Clin Mol Hepatol. 2025 Apr;31(2):e180-e182. doi: 10.3350/cmh.2025.0125. Epub 2025 Feb 13.
2
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023.
Clin Mol Hepatol. 2025 Apr;31(2):382-393. doi: 10.3350/cmh.2024.0987. Epub 2024 Nov 29.
3
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".
Clin Mol Hepatol. 2025 Apr;31(2):e183-e185. doi: 10.3350/cmh.2025.0152. Epub 2025 Feb 17.
4
5
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".
Clin Mol Hepatol. 2025 Apr;31(2):620-624. doi: 10.3350/cmh.2024.1131. Epub 2024 Dec 26.
6
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
J Hepatol. 2024 Dec;81(6):930-940. doi: 10.1016/j.jhep.2024.06.036. Epub 2024 Jul 4.
7
8
Exploring the landscape of steatotic liver disease in the general US population.
Liver Int. 2023 Nov;43(11):2425-2433. doi: 10.1111/liv.15695. Epub 2023 Aug 17.
9
Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
Hepatology. 2024 Jun 1;79(6):1393-1400. doi: 10.1097/HEP.0000000000000664. Epub 2023 Nov 1.
10
Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Metabolism. 2024 Apr;153:155800. doi: 10.1016/j.metabol.2024.155800. Epub 2024 Jan 22.
本文引用的文献
1
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".
Clin Mol Hepatol. 2025 Apr;31(2):620-624. doi: 10.3350/cmh.2024.1131. Epub 2024 Dec 26.
2
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023.
Clin Mol Hepatol. 2025 Apr;31(2):382-393. doi: 10.3350/cmh.2024.0987. Epub 2024 Nov 29.
3
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.
Clin Mol Hepatol. 2025 Jan;31(1):74-89. doi: 10.3350/cmh.2024.0631. Epub 2024 Oct 23.
4
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
Gut. 2024 Oct 7;73(11):1883-1892. doi: 10.1136/gutjnl-2024-333074.
5
Current epidemiology of chronic liver disease.
Gastroenterol Rep (Oxf). 2024 Jun 24;12:goae069. doi: 10.1093/gastro/goae069. eCollection 2024.
6
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
JAMA. 2024 Apr 16;331(15):1287-1297. doi: 10.1001/jama.2024.1447.
7
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
Clin Mol Hepatol. 2023 Oct;29(4):831-843. doi: 10.3350/cmh.2023.0277. Epub 2023 Aug 25.
8
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.
Clin Mol Hepatol. 2023 Feb;29(Suppl):S43-S57. doi: 10.3350/cmh.2022.0351. Epub 2022 Nov 22.
Zotero 插件